425: Enzon, Viskase Amend Merger Terms, Extend Deadline

Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, adjusting ownership ratios, reducing cash requirements, and extending the closing deadline to March 2026.

Summary

• The Merger Agreement and Support Agreement between Enzon Pharmaceuticals, Inc. and Viskase Companies, Inc. were amended on October 24, 2025.
• Viskase stockholders will now own 55% of the combined company following the Merger, while Enzon stockholders will own 45%.
• The exchange ratio for Enzon's Series C Non-Convertible Redeemable Preferred Stock will be based on the 20-day volume weighted average price (20-Day VWAP) of Enzon Common Stock prior to October 24, 2025.
• The minimum amount of cash Enzon is required to have at the closing of the Merger has been reduced to $40,000,000.
• Enzon will effect a 1-for-100 reverse stock split with respect to all shares of Enzon Common Stock prior to the effective time of the Merger.
• The termination date for the Merger Agreement has been extended from December 31, 2025, to March 31, 2026.
• Enzon and Merger Sub waived, consented to, and released any known inaccuracies, breaches, or failures to comply by Viskase occurring on or prior to October 24, 2025.
• The definition of 'Viskase Material Adverse Effect' was modified to exclude facts known by Enzon, Merger Sub, or their representatives prior to October 24, 2025.
• Icahn Enterprises Holdings L.P. (IEH) and its affiliates agreed to deliver written consents approving the Merger and Enzon's certificate of incorporation amendment, and to exchange their Series C Preferred Stock for Enzon Common Stock based on liquidation preference and the 20-Day VWAP.
• The combined company's name is anticipated to be Viskase Holdings, Inc.
• Enzon believes the revised Merger will allow its net operating losses and other tax benefits to be maintained and available for the combined company.

Sentiment

Score: 3

Explanation: The amendments reflect a less favorable outcome for Enzon's existing shareholders due to increased Viskase ownership, a significant reverse stock split, reduced cash requirements, and waivers of Viskase breaches. While the merger is proceeding, the revised terms suggest underlying challenges or a re-evaluation that benefits Viskase more than Enzon.

Positives

• The amendments indicate continued commitment to the merger, providing clarity on the path forward for both companies.
• Enzon believes its net operating losses and other tax benefits will be preserved for the combined entity, which could be a significant asset.
• Special Committees of independent directors from both Enzon and Viskase recommended and approved the amendments, suggesting a thorough review and determination of fairness.
• Icahn Enterprises Holdings L.P.'s agreement to support the merger and convert its preferred stock simplifies the capital structure and ensures a major shareholder's backing.

Negatives

• Viskase stockholders' increased ownership to 55% of the combined company implies a reduced stake for existing Enzon shareholders (45%), suggesting a less favorable valuation for Enzon.
• The reduction in Enzon's minimum cash requirement at closing to $40,000,000 could indicate a weaker financial position or revised capital needs for Enzon.
• Enzon and Merger Sub waived known breaches by Viskase, which could expose the combined company to undisclosed liabilities or operational issues.
• The 1-for-100 reverse stock split is a significant consolidation, often perceived negatively by the market as it typically follows a prolonged period of low stock prices.
• The extension of the merger termination date by three months suggests delays and potential difficulties in closing the transaction as originally planned.

Risks

• Conditions to the closing of the proposed transaction may not be satisfied, including the failure to obtain necessary approvals.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction and the ability of each of Enzon and Viskase to close.
• Viskase's ability to timely deliver the financial statements required by the Merger Agreement, as amended, is a factor.
• Anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, growth, and tax treatment, may not be realized.
• Potential litigation relating to the proposed transaction could be instituted against Enzon, Viskase, or their respective officers or directors.
• Possible disruptions from the proposed transaction could harm Enzon's or Viskase's respective businesses.
• Viskase's ability to retain, attract, and hire key personnel is a concern.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties may result from the announcement or completion of the proposed transaction.
• Business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction could affect Enzon's or Viskase's financial performance.
• Certain restrictions during the pendency of the proposed transaction may impact Enzon's or Viskase's ability to pursue certain business opportunities or strategic transactions.
• The exchange ratio and relative ownership levels as of the closing of the transactions contemplated by the Merger Agreement, as amended, are subject to change.
• Estimates regarding future revenue, expenses, and capital requirements following the closing of the transactions contemplated by the Merger Agreement, as amended, may be inaccurate.
• Legislative, regulatory, and economic developments could impact the transaction.
• Unpredictability and severity of catastrophic events, including acts of terrorism, trade wars, or outbreak of war or hostilities, as well as management's response to these factors, pose risks.

Future Outlook

Enzon intends to prepare and file a registration statement on Form S-4 with the SEC, which will include a consent solicitation statement, to seek stockholder approval for the amended merger agreement, the change of the combined company's name to Viskase Holdings, Inc., and the 1-for-100 reverse stock split. The company believes the revised merger will allow Enzon's net operating losses and other tax benefits to be maintained and available for use by the combined company.

Management Comments

• Enzon believes that the Merger as revised pursuant to the terms of the Merger Agreement Amendment will result in Enzon's net operating losses and other tax benefits to be maintained and available for use by the combined company following the Merger.

Industry Context

This filing details an amendment to a merger agreement between Enzon Pharmaceuticals, Inc., described as a public company acquisition vehicle, and Viskase Companies, Inc., a global producer of non-edible cellulosic, fibrous, and plastic casings for processed meat products. Viskase operates nine manufacturing facilities across North America, Europe, South America, and Asia, selling products in nearly one hundred countries. The merger represents a strategic pivot for Enzon into the food packaging industry, aiming to leverage its public listing and potentially its tax assets for Viskase's established global business.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the merger terms against industry benchmarks.
• The 1-for-100 reverse stock split is a significant consolidation, often observed in companies with very low share prices seeking to meet listing requirements or improve market perception, but it does not inherently compare to industry operational standards.
• The shift in ownership to 55% for Viskase shareholders suggests a re-evaluation of relative contributions, which could be compared to typical merger premiums or control premiums in similar industry transactions, but no such data is provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Enzon, Viskase, or their respective officers or directors is listed as a risk.

Related Party Transactions

• Icahn Enterprises Holdings L.P. (IEH) and certain of its affiliates are parties to the Support Agreement and its amendment with Enzon and Viskase.
• IEH agreed to deliver written consents for all of its Enzon Common Stock approving the Merger and the amendment to Enzon's certificate of incorporation.
• IEH agreed to exchange all of its Series C Preferred Stock for Enzon Common Stock prior to the consummation of the Merger, based on the full liquidation preference and the 20-Day VWAP.

Stakeholder Impact

• **Enzon Shareholders:** Experience a reduction in their implied ownership percentage of the combined company (from 55% to 45%) and will undergo a 1-for-100 reverse stock split. They are required to approve the merger amendments and corporate charter changes.
• **Viskase Shareholders:** Will hold an increased ownership percentage (55%) in the combined company.
• **Employees (Viskase):** Face a risk regarding the ability to retain, attract, and hire key personnel during and after the merger.
• **Customers, Suppliers, and Other Parties (Enzon & Viskase):** May experience potential adverse reactions or changes to relationships resulting from the announcement or completion of the proposed transaction.

Next Steps

• Enzon will prepare and file a registration statement on Form S-4 with the SEC, which will include a consent solicitation statement.
• Enzon will seek written consent from its stockholders regarding the amended Merger Agreement, the change of the combined company's name to Viskase Holdings, Inc., and the 1-for-100 reverse stock split.
• Enzon will effectuate the 1-for-100 reverse stock split with respect to all shares of Enzon Common Stock prior to the effective time of the Merger.
• Icahn Enterprises Holdings L.P. and its affiliates will exchange all of their Series C Preferred Stock for Enzon Common Stock prior to the consummation of the Merger.
• Enzon's Board of Directors will permit the Section 382 Rights Agreement to expire or be terminated in accordance with its terms prior to the Effective Time.

Key Dates

Recommendation

The amended merger terms introduce significant changes, including a reduced ownership stake for Enzon shareholders, a substantial reverse stock split, and waivers of Viskase breaches. While the merger is progressing, these adjustments suggest a less favorable valuation for Enzon and potential underlying issues. The extension of the closing deadline also indicates delays. Given the uncertainties and the less advantageous terms for Enzon's current shareholders, a 'hold' recommendation is appropriate until the full implications of the revised merger and the combined entity's prospects become clearer, especially after the Form S-4 filing and further financial disclosures.

Keywords

Enzon Pharmaceuticals, Viskase Companies, Merger Agreement Amendment, Reverse Stock Split, Corporate Acquisition, Shareholder Ownership, Preferred Stock Exchange, Tax Benefits, Corporate Governance, SEC Filing, OTC Markets, Financial Reporting